Innovation & Growth with Kimberly-Clark's Patricia Corsi & Craig Slavtcheff
The CPG Guys are joined in this episode by Particia Corsi, Chief Growth Officer & Craig Slavtcheff, Chief R&D Officer at Kimberly-Clark, manufacturer of trusted brands that are an indispensable part of life for people in more than 175 countries and territories. The portfolio of brands, including Huggies, Kleenex, Scott, Kotex, Cottonelle, Poise, Depend, Andrex, Pull-Ups, Goodnites, Intimus, Plenitud, Sweety, Softex, Viva and WypAll, hold No. 1 or No. 2 share positions in approximately 70 countries. Our company's purpose is to deliver Better Care for a Better World. Follow Patricia on LinkedIn at: https://www.linkedin.com/in/patriciacorsi/Follow Craig on LinkedIn at: https://www.linkedin.com/in/craig-stephen-slavtcheff-7115455/Follow Kimberly-Clark online at: https://www.kimberly-clark.com/en-us/They answer these questions;Under the 'Powering Care' strategy, you talk about the need to 'out-innovate, out-market, and out-activate' together. Practically speaking, how have you re-wired your teams to work in lockstep? Does R&D sit in on the creative briefings now?How do you engineer that kind of premium performance into a value-tier product without breaking the margin structure? That seems like an R&D magic trick.Can you give us an example of a product that worked in one market that you rapidly adapted and deployed to another? How are you customizing for local needs without losing the efficiency of a global chassis?How do you balance the functional 'science' that Craig’s team builds with the 'brand love' you need to build? Can you talk about the creative strategy behind your recent Cannes wins and how that translates to actual market share gains?How is Kimberly-Clark 'breaking through the noise' right now? Is it about being more provocative with the creative, or is it about being more precise with the targeting?You’ve just wrapped year two of the 'Powering Care' transformation—the largest in the company’s 154-year history. And now, you have the Kenvue deal on the horizon later this year. When you look at the combined potential of these portfolios, how does your mission to 'raise the standard of care' evolve? What